

| Country Demographics ^{1,2,3} | |
|---|-------------|
| Total population (2017) ¹ | 276,255 |
| Urban population (% of total, 2016) ¹ | 71% |
| Health expenditure per capita (\$US, 2016) ² | NR |
| Health expenditure, total (% of GDP, 2016) ² | NR |
| Total births (2017) ¹ | 4,304 |
| Surviving infants (2017) ¹ | 4,254 |
| Life expectancy at birth (years, 2017) ² | 77.1 yrs |
| Number of districts (2012) ³ | 3 provinces |


| HBsAg Prevalence ⁶ | |
|-------------------------------|----|
| Pre-vaccine HBsAG+ (%) | 6% |

| Liver Cancer as Cause of Cancer Death (in Men) ⁵ | |
|---|------------|
| Year: 2018 | Ranking: 4 |


| 2018 Country Comparison in Western Pacific Region (37 Member States/Areas) ⁴ | | | | |
|---|---------------|--|--|---|
| | New Caledonia | Number of member states with WHO-UNICEF estimated coverage | Highest WHO-UNICEF estimated coverage in WPR | Lowest WHO-UNICEF estimated coverage in WPR |
| HepB3 ⁴ | NR | 26 | 99% (Brunei Darussalam, China, Cook Islands, Fiji, Malaysia, Mongolia, Niue) | 34% (Samoa) |
| HepB BD ⁴ | NR | 24 | 99% (Brunei Darussalam, Cook Islands, Palau, Tuvalu) | 25% (Papua New Guinea) |

| Hepatitis B Immunization Coverage ^{4,7,8} | | | | | | | | | | | | | | | | | | | *These are official country estimates, not WHO-UNICEF estimates. | |
|--|------|------|------|------|------|------|-------|-------|-------|------|------|------|-------|-------|-------|------|------|------------------|--|--|
| | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | |
| HepB3 ⁷ | NR | NR | NR | NR | NR | NR | 99% | 97.8% | 97.8% | 98% | 98% | 98% | 92.8% | 92.8% | 92.8% | 93% | 93% | 93% ⁸ | NR ⁴ | |
| HepB BD ⁷ | NR | NR | NR | NR | NR | NR | NR | 98.6% | 98.6% | 99% | 99% | 99% | 97.6% | 97.6% | 97.6% | 98% | 98% | 98% ⁸ | NR ⁴ | |
| DTP3 ⁷ | NR | NR | NR | NR | NR | NR | 100% | 100% | 100% | 100% | 100% | 100% | 98.3% | 98.3% | 98.3% | 98% | 98% | NR | NR ⁴ | |
| BCG ⁷ | NR | NR | NR | NR | NR | NR | 99.5% | 98% | 98% | 98% | 98% | 98% | 95.7% | 95.7% | 95.7% | 96% | 96% | NR | NR ⁴ | |

New Caledonia: HepB3 vs. DTP




New Caledonia: HepB BD vs. BCG



Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAg= HepB surface antigen. Data Compiled by APAVH 2019: WHO WPRO Hepatitis B control: country profile 2017¹, World DataBank: World Development Indicators database², NationMaster Country Profiles³, WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary Official Country Estimates⁴, Global Cancer Observatory: Cancer Today-IARC⁵, Western Pacific Regional Plan for Hepatitis B control through Immunization⁶, WHO West Pacific Region Health Information and Intelligence Platform (HIIP): Immunization Coverage⁷, Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus — Western Pacific Region, 2005–2017⁸, National Immunization Data – EPI summaries by country⁹

| National Policies on Hepatitis B Screening for Pregnant Women | |
|--|--|
| Mandatory HepB screening in all pregnant women (Y/N) | |
| -If Y, mandatory reporting of HBs-Ag positive pregnant women to public health department (Y/N) | |
| HBIG administered with HepB BD to infants born to HBsAg positive women (Y/N) | |
| - If Y, is it free? (Y/N) | |

| National Policies on Hepatitis B Immunization ⁹ | |
|--|-----------------------|
| Universal newborn HepB immunization (Y/N) ⁹ | Y |
| - If Y, year introduced ⁹ | 1989 |
| -HepB3 nationwide ⁹ | NR |
| -Free for all newborns (Y/N) | |
| -If free, state year introduced: | |
| Catch-up immunization program for unvaccinated children (Y/N) | |
| - If Y, year introduced | |
| -Free for all unvaccinated children (Y/N) | |
| -If free, state year introduced: | |
| Immunization program for health care workers (Y/N) | |
| - If Y, year introduced | |
| -Free for all health care workers(Y/N) | |
| -If free, state year introduced: | |
| HepB newborn immunization included in multiyear plan for EPI (Y/N) | |
| HepB BD in schedule (Y/N) ⁹ | Y |
| Systems to monitor HepB BD ⁹ | Hospitals, HCs, Homes |
| Systems to deliver HepB BD ⁹ | Hospitals, HCs, Homes |
| HepB vaccine funding other than country government (Y/N) | |
| -If Y, please specify funding source: | |



| National Policies on Chronic Hepatitis B Treatment | |
|--|--|
| Treatment for chronic HBV infection covered (Y/N) | |
| - If Y, year introduced | |
| -Interferon (Y/N) | |
| -Oral antiviral (Y/N) | |

| Certification Status ¹ | |
|--------------------------------------|----------------|
| Year certification report received | Pending (2017) |
| Year certification panel convened | NR |
| Year certification approved | NR |
| Approved with prevalence <1% or <2%? | NR |

Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAg= HepB surface antigen. Data Compiled by APAVH 2019: WHO WPRO Hepatitis B control: country profile 2017¹, World DataBank: World Development Indicators database², NationMaster Country Profiles³, WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary Official Country Estimates⁴, Global Cancer Observatory: Cancer Today-IARC⁵, Western Pacific Regional Plan for Hepatitis B control through Immunization⁶, WHO West Pacific Region Health Information and Intelligence Platform (HIIP): Immunization Coverage⁷, Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus — Western Pacific Region, 2005–2017⁸, National Immunization Data – EPI summaries by country⁹